High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome
Tomoki Origuchi1,2 , Kazuhiko Arima2 , Shin-ya Kawashiri2 , Mami Tamai2 , Satoshi Yamasaki2 , Hideki Nakamura2 , Toshiaki Tsukada3 , Toshiyuki Aramaki4 , Masako Furuyama5 , Taiichiro Miyashita6 , Yojiro Kawabe7 , Nozomi Iwanaga8, Kaoru Terada8, Yukitaka Ueki8, Takaaki Fukuda9, Katsumi Eguchi10, Atsushi Kawakami2
4 August 2011
31 October 2011
17 November 2011
PDF (member's only)
Recently, it was reported that remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome could be complicated with solid tumors. In a retrospective, multicenter study between October, 2003 and September, 2010, we investigated the characteristics of patients with paraneoplastic RS3PE syndrome who fulfilled following criteria: (1) bilateral pitting edema of hands or feet or both, (2) sudden onset of polyarthritis, and (3) age >50 years, (4) seronegativity for rheumatoid factor (RF). A total of 33 cases fulfilled the above criteria. Eight patients (seven men and one woman) developed cancer within 2 years of RS3PE syndrome onset. There was no significant difference between the neoplastic and nonneoplastic groups in the proportions of patients with fever, symmetrical polyarthritis, pitting edema, and good response to corticosteroids. Serum matrix metalloproteinase 3 (MMP-3) level (median 437.3 ng/ml) in the paraneoplastic RS3PE patients was significantly higher than that in patients without neoplasia (median 114.7 ng/ml) (p<0.05). We found that high serum MMP-3 is characteristic of patients with paraneoplastic RS3PE syndrome.
Remitting seronegative symmetrical synovitis with pitting edema syndrome (RS3PE syndrome) - Matrix metalloproteinase 3 - Neoplasia